)
ADMA Biologics (ADMA) investor relations material
ADMA Biologics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key business updates and financial performance
Pre-announced 2025 revenue of over $510 million, with Q4 revenue exceeding $139 million and EBITDA of $77–78 million; net income above $50 million, a significant increase from Q3 2025.
2026 revenue guidance is $635 million, with $360 million EBITDA; 2027 guidance is $775 million revenue and $455 million EBITDA.
2029 revenue target is $1.1 billion, with $700 million EBITDA, not including potential from pipeline product SG01.
2025 preliminary unaudited financials show $88 million in cash and over $40 million in operating cash flow; ongoing share buybacks.
Divestiture of three plasma centers for $12 million gross proceeds, reducing operating costs by $13–15 million.
Product innovation and market strategy
ASCENIV, a unique polyclonal immunoglobulin, is protected by IP through 2035 and targets about 10% of the PI population, with current penetration at 4%.
Yield enhancement manufacturing strategy approved in April 2025 enables 20% more finished goods from the same plasma, driving margin and revenue growth.
100% of ASCENIV sold in Q4 2025 was yield-enhanced; 2026 will be the first full year of yield-enhanced production.
Real-world evidence shows significant reductions in infections and hospitalizations for ASCENIV users, supporting further market penetration.
Direct-to-patient education and advocacy programs are expanding ASCENIV's reach.
Supply chain, operations, and partnerships
Operates 10 plasma centers, with 85% of raw material sourced from third parties; new long-term supply contracts expand collection network to over 280 centers.
End-to-end U.S. supply chain control insulates from tariffs and import/export risks; all products sold domestically.
New distribution agreement with McKesson Specialty broadens reach in immunology and oncology settings.
Strategic divestiture of plasma centers optimizes inventory and cost structure while maintaining access to high-titer donors.
Next ADMA Biologics earnings date
Next ADMA Biologics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)